-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, J7gdiW4x/tc+8qKgDndnfZQWsW3LuDZYwPsl38L4i1eD6ad8SGUu4JJqgA/EgShp asoIKPV2qQVI4uk205cxdA== 0001144204-10-044759.txt : 20100816 0001144204-10-044759.hdr.sgml : 20100816 20100816165708 ACCESSION NUMBER: 0001144204-10-044759 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100630 FILED AS OF DATE: 20100816 DATE AS OF CHANGE: 20100816 EFFECTIVENESS DATE: 20100816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 101020623 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v193795_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: June 30, 2010 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 21st Floor -------------------------------------------- New York, NY 10065-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. August 13, 2010 - -------------------------- --------------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 60 ----------- Form 13F Information Table Entry Value: $1,765,785 ----------- (thousands) List of Other Included Managers: None Baker Brothers Form 13F 6-30-2010
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ---------------------------- ------- ------- ------- --- ---- ---------- -------- ---- ------ ---- Achillion COM 00448Q201 2,090 950,000 SH SOLE 950,000 Acorda Therapeutics COM 00484M106 31,110 1,000,000 SH SOLE 1,000,000 Adolor Corp. COM 00724X102 7,770 7,128,659 SH SOLE 7,128,659 Allos Therapeutics Inc. COM 019777101 10,634 1,734,794 SH SOLE 1,734,794 Alsius Corp. COM 021211107 3 62,872 SH SOLE 62,872 Amicus Therapeutics COM 03152W109 1,794 800,697 SH SOLE 800,697 Amylin Pharmaceuticals COM 032346108 1,865 99,180 SH SOLE 99,180 Anadys Pharmaceuticals Inc. COM 03252Q408 463 241,302 SH SOLE 241,302 AP Pharma COM 00202J203 4,186 6,861,818 SH SOLE 6,861,818 Aradigm Corp. COM 038505301 11 100,000 SH SOLE 100,000 Ardea Biosciences Inc. COM 03969P107 116,094 5,646,589 SH SOLE 5,646,589 Autoimmune Inc. COM 052776101 6 13,050 SH SOLE 13,050 Auxilium COM 05334D107 137,421 5,847,707 SH SOLE 5,847,707 Avanir Pharmaceuticals COM 05348P401 1,285 500,000 SH SOLE 500,000 Biocryst Pharmaceuticals Inc. COM 09058V103 32,881 5,563,615 SH SOLE 5,563,615 Biomarin COM 09061G101 6,835 360,515 SH SOLE 360,515 Bristol Myers COM 110122108 4,988 200,000 SH SOLE 200,000 Cadence Pharmaceuticals COM 12738T100 4,184 596,818 SH SOLE 596,818 Chelsea Therapeutics COM 163428105 544 185,709 SH SOLE 185,709 Cornerstone BioPharma COM 22674T105 662 112,337 SH SOLE 112,337 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 83 22,355 SH SOLE 22,355 Cumberland Pharmaceuticals COM 230770109 619 96,381 SH SOLE 96,381 Dendreon Corp. COM 24823Q107 17,018 526,390 SH SOLE 526,390 Depomed COM 249908104 513 183,145 SH SOLE 183,145 Genomic Health Inc. COM 37244C101 78,349 6,059,431 SH SOLE 6,059,431 Halozyme Therapeutics Inc. COM 40637H109 23,905 3,395,667 SH SOLE 3,395,667 Human Genome COM 444903108 6,864 302,910 SH SOLE 302,910 Idera Pharmaceuticals Inc. COM 45168K108 1,038 288,401 SH SOLE 288,401 Incyte Corp. COM 45337C102 145,830 13,173,417 SH SOLE 13,173,417 Infinity Pharmaceuticals Inc. COM 45665G303 2,373 401,602 SH SOLE 401,602 Inhibitex Inc. COM 45719T103 3,575 1,402,153 SH SOLE 1,402,153 Inspire COM 457733103 9,980 2,000,000 SH SOLE 2,000,000 Intermune Inc. COM 45884X103 7,236 773,886 SH SOLE 773,886 Inverness Medical COM 46126P106 49,253 1,847,463 SH SOLE 1,847,463 Lexicon Pharmaceuticals COM 528872104 960 750,000 SH SOLE 750,000 Ligand Pharmaceuticals Inc. CLASS B 53220K207 732 501,697 SH SOLE 501,697 Micromet COM 59509C105 25,739 4,124,911 SH SOLE 4,124,911 Neurogesx COM 641252101 1,185 178,681 SH SOLE 178,681 Pharmacyclics Inc. COM 716933106 4,266 640,578 SH SOLE 640,578 Pharmasset Inc. COM 71715N106 13,129 480,220 SH SOLE 480,220 Pharmathene COM 71714G102 518 323,807 SH SOLE 323,807 Salix Pharmaceuticals, Inc. COM 795435106 23,807 609,969 SH SOLE 609,969 Seattle Genetics Inc. COM 812578102 209,622 17,483,142 SH SOLE 17,483,142 Sucampo CLASS A 864909106 227 64,387 SH SOLE 64,387 Targacept COM 87611R306 2,762 142,873 SH SOLE 142,873 Threshold Pharma COM 885807107 3,721 3,075,390 SH SOLE 3,075,390 Trimeris Inc. COM 896263100 7,476 3,461,175 SH SOLE 3,461,175 Via Pharmaceuticals COM 92554T103 10 102,881 SH SOLE 102,881 Viropharma Inc. COM 928241108 117,280 10,462,071 SH SOLE 10,462,071 YM Biosciences COM 984238105 1,926 1,660,000 SH SOLE 1,660,000 Ziopharm Oncology Inc. COM 98973P101 3,323 1,045,000 SH SOLE 1,045,000 Zymogenetics COM 98985T109 4,668 1,106,250 SH SOLE 1,106,250 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 6,147 6,250,000 PRN SOLE 6,250,000 Biomarin Pharmaceuticals Notes 1.875% 4/23/2017 CONV BONDS 09061GAD3 4,144 3,910,000 PRN SOLE 3,910,000 Human Genome 2.25% 10/15/11 CONV BONDS 444903AK4 10,238 6,500,000 PRN SOLE 6,500,000 Incyte Genomics Notes 4.75% 10/1/2015 CONV BONDS 45337CAH5 237,600 160,000,000 PRN SOLE 160,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 28,104 29,313,000 PRN SOLE 29,313,00 Intermune Inc Notes 5% 3/1/15 CONV BONDS 45884XAD5 21,724 25,900,000 PRN SOLE 25,900,000 Salix 144A 5.5% 8/15/28 CONV BONDS 795435AB2 190,015 44,500,000 PRN SOLE 44,500,000 Salix 2.75% 5/15/15 CONV BONDS 795435AC0 135,000 125,000,000 PRN SOLE 125,000,000
-----END PRIVACY-ENHANCED MESSAGE-----